U
STAB

UBS’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

UBS’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$4K Buy
491
+351
+251% +$3.22K ﹤0.01% 9667
2014
Q2 		$1K Hold
140
– – ﹤0.01% 10262
2014
Q1 		$2K Sell
140
-415
-75% -$6.76K ﹤0.01% 10082
2013
Q4 		$13K Sell
555
-32
-5% -$870 ﹤0.01% 8722
2013
Q3 		$18K Sell
587
-62
-10% -$2.05K ﹤0.01% 8211
2013
Q2 		$21K Buy
+649
New +$22.3K ﹤0.01% 7847

Other funds holding STAB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's STAB Position: Q3 2014 in Review

UBS increased its Statera Biopharma, Inc. Common Stock (STAB) stake by 251% in Q3 2014, buying an estimated $3.22K and bringing the position to 491 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #9667.

UBS first reported a position in STAB in Q2 2013 and has held it in 6 quarters since. The position peaked at $21K in Q2 2013. 25 funds tracked by Wall St. Rank hold STAB as of Q3 2014.

  • UBS held 491 shares of Statera Biopharma, Inc. Common Stock worth $4K as of Q3 2014.
  • UBS bought 351 Statera Biopharma, Inc. Common Stock shares in Q3 2014, an estimated $3.22K.
  • Statera Biopharma, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9667 holding.
  • UBS first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's Statera Biopharma, Inc. Common Stock position peaked at $21K in Q2 2013.
  • 25 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.